Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face

Figure 1

Clinical images. Photographs of the patient at the time of initial presentation (a), after 4 months of vismodegib therapy (b), and at first follow-up, 2 months after completion of trimodality therapy (c).

(a)

(b)

(c)